Brainsway (BWAY.TA) Stock Price
Brainsway Price
Revenue has compounded at 53.7% per year over the past 15 years to 56.53 M USD. Brainsway's net margin stands at 14.6%, up from -21.8% several years earlier. Analysts set a median price target of 6.25 USD, implying 46.3% below the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Brainsway stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Brainsway business model & stock analysis
Frequently asked questions about Brainsway
Brainsway Ltd is a leading company in the field of neuroscience and mental health. Its business model revolves around the development and commercialization of advanced non-invasive medical devices for treating various brain disorders. Brainsway manufactures and markets Deep Transcranial Magnetic Stimulation (dTMS) systems, which are scientifically proven to be effective in treating major depressive disorder and obsessive-compulsive disorder. By leveraging cutting-edge technology and clinical expertise, Brainsway aims to provide patients with safe, non-pharmacological treatment options that can significantly improve their quality of life.
Brainsway Ltd is primarily active in the medical technology and healthcare industry.
The main competitors of Brainsway Ltd in the market are Magstim, Nexstim, and Neuronetics.
Brainsway Ltd. is a leading medical technology company specializing in the field of neuroscience. Established in 2003, Brainsway has been at the forefront of developing and commercializing breakthrough therapies for various brain disorders. The company is known for its innovative Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which provides non-invasive and effective treatment options for psychiatric and neurological conditions, such as major depressive disorder and obsessive-compulsive disorder. Brainsway has a strong commitment to research and development, constantly striving to improve the lives of patients worldwide. With its proven track record, Brainsway Ltd. continues to be a prominent player in the neurostimulation market, offering hope and transformative solutions to those in need.
Brainsway Ltd has achieved significant milestones since its inception. The company has made notable advancements in the field of non-invasive brain stimulation technology. Some of its key achievements include the development and commercialization of Deep Transcranial Magnetic Stimulation (dTMS) systems, earning FDA clearance for various indications such as major depressive disorder and obsessive-compulsive disorder. Brainsway Ltd has also expanded its global presence by establishing partnerships with renowned medical institutions and distributors worldwide. These milestones demonstrate Brainsway Ltd's commitment to revolutionizing the treatment of psychiatric and neurological disorders through innovative and effective technologies.
Brainsway Ltd, a global leader in non-invasive brain stimulation technologies, is primarily present in multiple countries and regions across the world. With its headquarters in Israel, Brainsway Ltd has established a strong presence in North America, including the United States and Canada. Additionally, the company has expanded its operations in Europe, with a significant presence in countries such as Germany, France, Italy, and the United Kingdom. Brainsway Ltd's innovative therapies and advanced technology have garnered recognition and adoption in numerous healthcare facilities and research centers worldwide.
Brainsway Ltd represents a strong commitment to advancing neurology and psychiatry through innovative technologies. The company is renowned for its deep transcranial magnetic stimulation (dTMS) system, offering effective and non-invasive treatment options for various brain disorders. Brainsway focuses on enhancing patients' quality of life by delivering cutting-edge solutions for depression, OCD, and other neuropsychiatric conditions. The company's corporate philosophy revolves around a patient-centric approach, striving to provide accessible and safe treatments worldwide. Brainsway's commitment to research and development, along with its collaborative partnerships with leading medical institutions, ensures ongoing advancements in neurological and psychiatric care.
Analysts currently set an average price target of 6.25 USD for the Brainsway stock (median: 6.25 USD), implying -46.3 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Brainsway stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Brainsway to generate revenue of 69.16 M USD and earnings per share of 0.58 USD.
Converted at the current exchange rate, the Brainsway share trades at 10.37 EUR (11.65 USD).
Brainsway Ltd is a leading company in the field of neuromodulatory technology specializing in non-invasive therapy options for neuropsychiatric disorders. The company utilizes its proprietary Deep TMS (Transcranial Magnetic Stimulation) platform to offer innovative therapy options for depression, obsessive-compulsive disorder, schizophrenia, ADHD, and other psychiatric disorders. The business model of Brainsway includes several business areas, including research and development, production, distribution, and clinical application. In the research and development area, the company works on developing and improving innovative neuromodulatory therapy options, collaborating closely with renowned academic institutions and clinical researchers worldwide. The production of Brainsway encompasses a wide range of neuromodulatory therapy devices and accessories used in clinical facilities worldwide. The company's offerings include therapy options for the treatment of depression, obsessive-compulsive disorder, schizophrenia, and ADHD. Brainsway provides various therapy devices specifically tailored to each indication, as well as accessories such as specialized electrodes to ensure the most effective treatment. In the distribution area, Brainsway relies on partnerships with medical device companies and clinics worldwide. The focus is on making the therapy options accessible to as many patients as possible and enabling medical professionals to have high flexibility and adaptability in the application of the therapy devices. Another core area of Brainsway's business model is the clinical application of its therapy options. The company collaborates with renowned institutions worldwide, offering its therapy devices and accessories for patient treatment. This collaboration involves working closely with physicians and clinics to ensure dosage and application regulation and maximize therapy effectiveness. Overall, Brainsway's business model is focused on the development and provision of innovative neuromodulatory therapy options for neuropsychiatric disorders. The company collaborates closely with researchers, medical professionals, and clinical facilities, offering a wide range of therapy devices and accessories for the treatment of various indications. Through close collaboration with medical device companies worldwide and a focus on each individual patient and practice, Brainsway aims to provide an effective and non-invasive treatment option for as many patients worldwide as possible.
The expected revenue of Brainsway is 69.16 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Brainsway is 24.47 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Brainsway is currently 20.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Brainsway stock.
The price-to-sales ratio (P/S) of Brainsway is currently 7.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Brainsway stock.
The Eulerpool Quality Score for Brainsway is 6/10.
The ISIN of Brainsway is IL0011007189. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Brainsway is A0NDVW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Brainsway is BWAY.TA. The ticker symbol is used to trade Brainsway shares on the stock exchange.
Brainsway stock
Brainsway Peer Group
Brainsway Ticker
Brainsway FIGI
All fundamentals and in-depth analysis of Brainsway
Our stock analysis for Brainsway stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brainsway. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.